peptides derived from anti-apoptotic proteins from the bcl-2 family,
Vaccineexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2010 (NCT01272466)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Apoptosis regulator Bcl-2Immunity, active
BCL2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- peptides derived from anti-apoptotic proteins from the bcl-2 family,
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01272466 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2010 | University of Copenhagen, University of Southern Denmark |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Copenhagen | Academic/Hospital | 1 | 1 | 1 | 2010 |
| University of Southern Denmark | Academic/Hospital | 1 | 0 | 1 | 2010 |
2 organizations
Page 1 / 1